Low-dose lovastatin safely lowers cholesterol after cardiac transplantation.

摘要: Hypercholesterolemia occurs in many cardiac transplant patients and may aggravate graft coronary arteriopathy as well contributing to peripheral vascular disease. Lovastatin, which inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase, doses of 40-80 mg/day effectively lowers cholesterol the general population but has been associated with rhabdomyolysis recipients. To determine whether lower lovastatin would be effective safe for lowering after transplantation, 44 blood greater than 200 mg/dl at least 6 months transplantation received 10-20 mg daily. In addition, enzyme inhibitor level was assayed six metabolism drug abnormal. Lovastatin decreased total by 28% from 282 +/- 54 208 62 (p less 0.005), primarily because reduction low-density lipoprotein fractions, well-tolerated without any symptoms or abnormal creatine phosphokinase levels 43 patients. One patient developed reversible renal failure when increased 40 Enzyme were 4.2-7.8 times higher those measured normal volunteers. Low-dose is altered, perhaps cyclosporine. Monitoring required allow administration this